TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder
Brief Summary: This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 2; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 3; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 4; Type: OTHER; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
C: Arm Label: S-DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Standard dialectical behavior therapy (SDBT) | Arm Label: DBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual DBT with no DBT group sessions (DBT-I) | Arm Label: DBT-S; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Skills DBT with no DBT individual sessions (DBT-S) | Intervention Type: BEHAVIORAL; Name: Standard dialectical behavior therapy (SDBT); Assigned to Arm(s): S-DBT | Intervention Type: BEHAVIORAL; Name: Individual DBT with no DBT group sessions (DBT-I); Assigned to Arm(s): DBT-I | Intervention Type: BEHAVIORAL; Name: Group Skills DBT with no DBT individual sessions (DBT-S); Assigned to Arm(s): DBT-S
D: Arm Label: Combined psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Combined psychotherapy | Arm Label: Outpatient individual psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient individual psychotherapy | Intervention Type: BEHAVIORAL; Name: Combined psychotherapy; Assigned to Arm(s): Combined psychotherapy | Intervention Type: BEHAVIORAL; Name: Outpatient individual psychotherapy; Assigned to Arm(s): Outpatient individual psychotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder
Brief Summary: This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
B: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
C: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Interpersonal effectiveness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interpersonal effectiveness | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness | Intervention Type: BEHAVIORAL; Name: interpersonal effectiveness; Assigned to Arm(s): Interpersonal effectiveness
D: Arm Label: Brief Admission; Type: EXPERIMENTAL; Interventions: Other: Brief Admission | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Brief Admission; Assigned to Arm(s): Brief Admission

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder
Brief Summary: This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.


Options:
A: Arm Label: MYPLAN app; Type: EXPERIMENTAL; Interventions: Other: MYPLAN-safety plan as an application for smart phones | Arm Label: Safety plan on paper; Type: ACTIVE_COMPARATOR; Interventions: Other: safety plan on paper | Intervention Type: OTHER; Name: MYPLAN-safety plan as an application for smart phones; Assigned to Arm(s): MYPLAN app | Intervention Type: OTHER; Name: safety plan on paper; Assigned to Arm(s): Safety plan on paper
B: Arm Label: TAU w/ mobile app + volunteer support; Type: EXPERIMENTAL; Interventions: Behavioral: Volunteer support, Other: Mobile app | Arm Label: TAU w/ mobile app engagement; Type: EXPERIMENTAL; Interventions: Other: Mobile app | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Volunteer support; Assigned to Arm(s): TAU w/ mobile app + volunteer support | Intervention Type: OTHER; Name: Mobile app; Assigned to Arm(s): TAU w/ mobile app + volunteer support, TAU w/ mobile app engagement
C: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
D: Arm Label: active anodal tDCS to ventrolateral prefrontal cortex (VLPFC); Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial direct current stimulation | Arm Label: sham anodal tDCS to VLPFC; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial direct current stimulation | Arm Label: Discontinued prior to randomization; Type: OTHER; Interventions: Other: No intervention | Intervention Type: DEVICE; Name: Transcranial direct current stimulation; Assigned to Arm(s): active anodal tDCS to ventrolateral prefrontal cortex (VLPFC), sham anodal tDCS to VLPFC | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Discontinued prior to randomization

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder
Brief Summary: This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.


Options:
A: Arm Label: SMS; Type: EXPERIMENTAL; Interventions: Device: SMS contact with patient after discharge in intervention group | Arm Label: Without SMS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: SMS contact with patient after discharge in intervention group; Assigned to Arm(s): SMS
B: Arm Label: Positive Psychology; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Psychology | Arm Label: Organizational Skills; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Positive Psychology; Assigned to Arm(s): Positive Psychology | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Organizational Skills
C: Arm Label: No text messages; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Supportive and interactive text messages; Type: EXPERIMENTAL; Interventions: Other: Supportive and interactive text messages | Intervention Type: OTHER; Name: Supportive and interactive text messages; Assigned to Arm(s): Supportive and interactive text messages
D: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder
Brief Summary: This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.


Options:
A: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention
B: Arm Label: Dialectical Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): Dialectical Behavior Therapy
C: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
D: Arm Label: CORE condition; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Healthy lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy lifestyle | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): CORE condition | Intervention Type: BEHAVIORAL; Name: Healthy lifestyle; Assigned to Arm(s): Healthy lifestyle

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder
Brief Summary: This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.


Options:
A: Arm Label: S-DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Standard dialectical behavior therapy (SDBT) | Arm Label: DBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual DBT with no DBT group sessions (DBT-I) | Arm Label: DBT-S; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Skills DBT with no DBT individual sessions (DBT-S) | Intervention Type: BEHAVIORAL; Name: Standard dialectical behavior therapy (SDBT); Assigned to Arm(s): S-DBT | Intervention Type: BEHAVIORAL; Name: Individual DBT with no DBT group sessions (DBT-I); Assigned to Arm(s): DBT-I | Intervention Type: BEHAVIORAL; Name: Group Skills DBT with no DBT individual sessions (DBT-S); Assigned to Arm(s): DBT-S
B: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omacor®; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Rexulti; Type: EXPERIMENTAL; Interventions: Drug: Rexulti | Intervention Type: DRUG; Name: Rexulti; Assigned to Arm(s): Rexulti | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Head to Head Comparison of Myfortic vs. Cellcept in the Treatment of Kidney Transplant Recipients Using Our Current Center Standardized Concomitant Immunosuppressive Protocol
Brief Summary: The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal transplant recipients.


Options:
A: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
B: Arm Label: 1: Myfortic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Sodium Delayed Release Tablets | Arm Label: 2. Cellcept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Mofetil | Intervention Type: DRUG; Name: Mycophenolate Sodium Delayed Release Tablets; Assigned to Arm(s): 1: Myfortic | Intervention Type: DRUG; Name: Mycophenolate Mofetil; Assigned to Arm(s): 2. Cellcept
C: Arm Label: Everolimus (EVR) & low dose of tacrolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus and tacrolimus | Arm Label: Mycophenolate mofetil & standard dose tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil and tacrolimus | Intervention Type: DRUG; Name: Everolimus and tacrolimus; Assigned to Arm(s): Everolimus (EVR) & low dose of tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil and tacrolimus; Assigned to Arm(s): Mycophenolate mofetil & standard dose tacrolimus
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Head to Head Comparison of Myfortic vs. Cellcept in the Treatment of Kidney Transplant Recipients Using Our Current Center Standardized Concomitant Immunosuppressive Protocol
Brief Summary: The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal transplant recipients.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C
B: Arm Label: Group 1 Standard Immunosuppression; Type: N/A; Interventions: N/A | Arm Label: Group 2 Campath Immunosuppression; Type: N/A; Interventions: N/A
C: Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
D: Arm Label: 1: Myfortic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Sodium Delayed Release Tablets | Arm Label: 2. Cellcept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Mofetil | Intervention Type: DRUG; Name: Mycophenolate Sodium Delayed Release Tablets; Assigned to Arm(s): 1: Myfortic | Intervention Type: DRUG; Name: Mycophenolate Mofetil; Assigned to Arm(s): 2. Cellcept

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma
Brief Summary: The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Elesclomol (STA-4783) | Arm Label: 2; Type: OTHER; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Elesclomol (STA-4783); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
B: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
C: Arm Label: Arm I (paclitaxel, carboplatin, sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm II (carboplatin, paclitaxel, placebo); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Pharmacological Study, Other: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate)
D: Arm Label: IMC-1121B (ramucirumab); Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab) | Arm Label: IMC-1121B (ramucirumab) + dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Dacarbazine | Intervention Type: BIOLOGICAL; Name: IMC-1121B (ramucirumab); Assigned to Arm(s): IMC-1121B (ramucirumab), IMC-1121B (ramucirumab) + dacarbazine | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): IMC-1121B (ramucirumab) + dacarbazine

Answer: D